Suggested remit: To appraise the clinical and cost effectiveness of nivolumab in combination with ipilimumab within its marketing authorisation for untreated metastatic non-small-cell lung cancer.
Company no longer pursuing a license in the UK
 
Status Suspended
Process STA 2018
ID number 1675

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
04 February 2020 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of nivolumab in combination with ipilimumab for untreated metastatic non-small-cell lung cancer ID1675. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal. However, the company that markets nivolumab and ipilimumab has advised NICE that they are no longer pursuing a licence in the UK for these products for this indication. In light of this information NICE will not be progressing with the scoping and appraisal exercise and consequently the scope consultation will be closed early. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on 44 (0)161 413 4070 or via email on emily.richards@nice.org.uk
04 February 2020 Suspended, Company no longer pursuing a license in the UK
18 December 2019 In progress, Referred December 5 2017

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance